The Latest Cardiac and Vascular News
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive share purchase agreement under which Stereotaxis will acquire Access Point Technologies EP (APT), a privately-held Minnesota-based developer of innovative electrophysiology catheters.
$5 million commitment will advance AHN’s Living Health model in Cardiovascular medicine, driving leading-edge clinical care, research and technological innovations for patients with atrial fibrillation and other heart rhythm disorders PITTSBURGH, May 10, 2024 /PRNewswire/ –…
R3 Vascular, Inc. announced the closing of its $87 million Series B financing round and the appointment of a new President and Chief Executive Officer
PONTE VEDRA, Fla., May 9, 2024 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in…
WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular announced today that Brian Walsh has been named Chief Executive Officer by the Cagent Vascular Board of Directors. He has served as Chairman of the Board since March 2018 and will continue in this capacity. Mr. Walsh will succeed Carol Burns as CEO. “It is a […]
PARIS–(BUSINESS WIRE)–Regulatory News: “I’m very pleased with the progress of the EFICAS study, both in terms of the pace of inclusion and results observed to date. ” Post this CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for […]
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.
Funding supports commercial expansion of inHEART’s digital twin of the heart in the US, EU, Asia Pacific, and Middle East markets, as well as the development of new software solutions across the cardiac care continuum CAMBRIDGE, Mass. and BORDEAUX, France, May 6, 2024 /PRNewswire/ –…
IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the upcoming Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024, at 11:20 AM Pacific Time.
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 30,000 of NewAmsterdam’s ordinary shares to three non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
